Synergy Pharmaceuticals Advances Its Preclinical Research Program For The Use Of Guanylate Cyclase C Agonists To Lower Cholesterol
18. Mai 2011 06:30 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTCQB:SGYP.PK), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has successfully completed preclinical...
Synergy Pharmaceuticals to Present at Bank of America Merrill Lynch Health Care Conference
03. Mai 2011 08:00 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced that Dr. Gary S. Jacob, President and Chief Executive...
Synergy Pharmaceuticals Appoints Dr. Laura Barrow as Vice President of Clinical Operations
22. März 2011 08:15 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTCQB:SGYP.OB), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today the appointment of Laura Barrow, Pharm. D. as...
Synergy Pharmaceuticals to Present at BIO-Europe Spring 2011 Conference
08. März 2011 08:15 ET
|
Synergy Pharmaceuticals
BIO-Europe Spring 2011
NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that Dr. Gary S. Jacob,...
Synergy Pharmaceuticals Granted U.S. Patent on SP-333, Synergy's Developmental Drug for Gastrointestinal Inflammatory Diseases
23. Februar 2011 05:00 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and...
Synergy Pharmaceuticals to Present at the 13th Annual BIO CEO and Investor Conference
07. Februar 2011 10:20 ET
|
Synergy Pharmaceuticals
BIO CEO & Investor Conference 2011
NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that...
Synergy Pharmaceuticals Announces New Clinical Development Plan for Plecanatide
07. Januar 2011 08:00 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTC BB:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to...
Synergy Pharmaceuticals Awarded Federal Grant to Support Further Development of Plecanatide to Treat Gastrointestinal Disorders
04. November 2010 15:35 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTC BB: SGYP), a developer of new drugs to treat gastrointestinal disorders (GI) and diseases, announced today that it has been awarded a $244,479 grant under...
Synergy Pharmaceuticals Announces Positive Phase IIa Results with Plecanatide to Treat Chronic Constipation
06. Oktober 2010 07:15 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today positive results in a Phase IIa clinical trial of...
Synergy Pharmaceuticals to Present at Roche Colorado Corporation Peptide Symposium 2010
14. September 2010 07:15 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that Dr. Kunwar Shailubhai, the Company’s Chief...